October 25, 2017 06:46 AM EDTUpdated 01:56 PM
R&D

In­cyte grabs a new PD-1 check­point drug in $900M deal with Macro­Gen­ics

John Carroll

Editor & Founder

In­cyte $IN­CY has just inked a $900 mil­lion deal to grab glob­al rights to an ear­ly-stage PD-1 check­point now be­ing de­vel­oped at Macro­Gen­ics.

The two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times